As part of our ongoing support for the PrEvCan – Cancer Prevention Across Europe – campaign, we were delighted to speak with the President of the European Oncology Nursing Society (EONS), Johan de Munter.
Initiated by EONS, and with ESMO as a key campaign partner, PrEvCan is based on the European Code Against Cancer (ECAC), which sets out 12 recommendations to reduce cancer burden.
From October 2022, each month of the PrEvCan campaign is dedicated to one of the ECAC recommendations. In this interview, we focus on the months of December 2022 through to February 2023, which encompasses the ECAC recommendations around diet, weight and physical activity. We discuss the scientific evidence behind these recommendations and lifestyle advice all HCPs can use to share with their patients and the wider community to help reduce cancer risk. We also touch on the ‘Waistline Challenge’ an activity designed by EONS to motivate patients to take action to be a healthy body weight.
- What is the basis of the PrEvCan campaign? (0:21)
- Could you give us an outline of the ECAC recommendations 3-5, which cover diet and physical activity? (1:08)
- What is known about the relationship between body weight and cancer risk? (1:48)
- What evidence underlies the recommendations on diet and exercise? (2:16
- What specific advice would you give regarding physical activity? (2:40)
- What activities will take place to promote these recommendations? (3:20)
Disclosures: Johan de Munter has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Learn more about the PrEvCan campaign, and download toolkits and videos to help you spread the PrEvCan messages here: https://cancernurse.eu/prevcan/
Share this Video
Related Videos In Policy
Raising awareness around HPV infection, cancer risk and vaccination: PrEvCan | Daniel Kelly
The PrEvCan – Cancer Prevention Across Europe – campaign, initiated by the European Oncology Nursing Society (EONS) and supported by ESMO, aims to reduce the burden of cancer by promoting a different way we can decrease cancer risk each month. This August, the PrEvCan campaign focuses on raising awareness about the connection between human papillomavirus […]
Vivek Subbiah, AACR 2023: The purpose of phase I clinical trials
The purpose of phase I clinical trials are to evaluate the safety, dosage and potential side effects of a new drug or treatment in humans for the first time. In this touchONCOLOGY interview, we speak with Dr Vivek Subbiah (University of Texas, MD Anderson Cancer Centre, Houston, TX, USA) to discuss the purpose and details […]
Vivek Subbiah, AACR 2023: The evolution of phase I clinical trials in the era of precision medicine
Precision medicine aims to tailor medical treatments to individual patients based on their characteristics and genetic makeup. Phase I clinical trials are seeing changes in their objectives and designs in the era of precision medicine. In this touchONCOLOGY interview, we speak with Dr Vivek Subbiah (University of Texas, MD Anderson Cancer Centre, Houston, TX, USA) […]